A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study.
about
Cancer of the endometrium: current aspects of diagnostics and treatmentHypoxia-inducible factor-1 as a therapeutic target in endometrial cancer managementDoes the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis.Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial.Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group studyPhase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancersCurrent treatment options for endometrial cancer.Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229NA phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial.Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009.Systemic therapy for recurrent endometrial cancer: a review of North American trials.Targeting NF-κB and HIF-1 pathways for the treatment of cancer: part II.Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease SettingsEfficacy of combination chemotherapy using irinotecan and nedaplatin for patients with recurrent and refractory endometrial carcinomas: preliminary analysis and literature review.Potential use of the adenosine triphosphate cell viability assay in endometrial cancer.Clinical Behavior and Treatment of Endometrial Cancer.
P2860
Q24797130-62859E71-9D48-409F-B987-B9AC3A46D7BEQ33652379-97EC47A2-DE58-41BF-955D-5FB772EA04BEQ33671891-E889C9E0-5BDE-4AD2-8514-DA6756B178EBQ34409341-96F5DBE6-406A-47E3-A400-75C2A3DEA42FQ35023418-1542C378-7D04-4134-B65F-5A219F9919F5Q35144264-A31D0176-E59C-44C9-90A4-F7539106EBBBQ35671530-C5E2BA6F-1C57-440B-88DB-592FFAFBE989Q35843726-6B024742-B4E4-4D44-9528-53E3059B3EB6Q36191443-E7644019-74D5-410D-8F0F-E142BE310AD1Q36407018-3BE37D56-30D1-4B13-A0CC-A3A368100092Q36960802-11BCF74E-3975-490C-AC1F-024BCFDD74C0Q37546032-EA2C4D06-04DB-49B1-B3E9-C870A176D9D1Q37882456-0F91491A-3DAA-403A-B14F-C9DE69C1C429Q38895754-3306852F-CD48-4905-B7B4-5D6077663B03Q48328979-E81E4245-8E32-4D23-979D-DBE4626F689BQ53599064-F4B56EC1-FCB5-4993-934C-6E8AE780D4ECQ54011680-A636C94E-8A00-43AA-B771-65A8C4473DAC
P2860
A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study.
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
A phase II trial of topotecan ...... ecologic oncology group study.
@ast
A phase II trial of topotecan ...... ecologic oncology group study.
@en
type
label
A phase II trial of topotecan ...... ecologic oncology group study.
@ast
A phase II trial of topotecan ...... ecologic oncology group study.
@en
prefLabel
A phase II trial of topotecan ...... ecologic oncology group study.
@ast
A phase II trial of topotecan ...... ecologic oncology group study.
@en
P2093
P356
P1433
P1476
A phase II trial of topotecan ...... ecologic oncology group study.
@en
P2093
John A Blessing
Samuel S Lentz
Steven E Waggoner
P304
P356
10.1006/GYNO.2002.6804
P407
P577
2002-12-01T00:00:00Z